Findings

What do systematic reviews say?

9 questions · 9 findings · 1 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 88.9%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Dalteparin vs placebo

Pain intensityVAS 0‐10. Scale from: 0 to 10. · sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 35 participants
Very low

Dalteparin vs placebo

Pain duration ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

The requirement for opiate treatment · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Number of serious complications of SCD ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Number of other sickle‐related events ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Hospitalisation (number and duration) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found